Xenoport Shares Boom, Company Sketches Out Sales Plan for New Drug
Summary
Xenoport, clearly anticipating this line of argument, is attempting to head it off by pointing to studies that suggest it is linked to more serious conditions like high blood pressure and heart disease.Xenoport’s share of the profits and losses will be determined on a sliding scale of between 20 and 50 percent of the drug’s finances, depending on its level of contribution to the partnership with Glaxo.Xenoport has three years to decide if it wants to build its own sales force to supplement the work of Glaxo’s team, said Bill Harris, the company’s chief financial officer.If Xenoport goes ahead with that plan, it would build a group of about 50 to 100 sales reps, said Vincent Angotti, the company’s chief commercial officer.Barrett said the FDA-cleared prescribing information includes language on how high doses—between 10 and 75 times the recommended human dose—appeared to be associated with the development of cancer in male and female rats.